Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The license agreement with an overseas pharmaceutical company, milestone revenue related to TLG-001, and the consolidation of メディプロデュース contributed to net sales. However, the Company recorded an operating loss due to research and development expenses, promotional expenses for the healthcare consumer products business, and operating and business expansion expenses for メディプロデュース, among other factors.
There are disclosures regarding significant events and other matters that raise substantial doubt about the going-concern assumption. However, after comprehensively considering the Company’s response measures and funding plan, the Company determined that no significant uncertainty exists. There are no applicable notes regarding the going-concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥491 million |
| Operating profit | ¥-331 million |
| Ordinary income | ¥-294 million |
| Profit attributable to owners of the parent | ¥-295 million |
| Net income per share | ¥(11.42) |
| Equity ratio | End of the current fiscal period 42.3 / End of previous period Not disclosed |
| Total assets | ¥1,463 million |
| Net assets | ¥622 million |
| Cash flows from operating activities | ¥-101,765 thousand |
| Cash flows from investing activities | ¥29,460 thousand |
| Cash flows from financing activities | ¥289,468 thousand |
| Cash and cash equivalents at end of period | ¥1,186,852 thousand |
| Full-year earnings forecast | Net Sales 1,400～1,800 / Operating profit 0～45 / Ordinary income 40～85 / Net income 40～85 |
| Revision to Earnings Forecast | Net Sales Not disclosed → 1,400～1,800 / Operating profit Not disclosed → 0～45 / Ordinary income Not disclosed → 40～85 / Net income Not disclosed → 40～85 |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | R&D business ¥437,906 thousand, PCO business ¥18,457 thousand, HC business ¥36,122 thousand |
| Segment profit | R&D business ¥-272,399 thousand, PCO business ¥-12,334 thousand, HC business ¥-44,684 thousand |
| Depreciation and amortization | ¥6,513 thousand |
| Disclosure regarding the going concern assumption | There are disclosures regarding significant events and other matters that raise substantial doubt about the going-concern assumption. However, after comprehensively considering the Company’s response measures and funding plan, the Company determined that no significant uncertainty exists. There are no applicable notes regarding the going-concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社メディプロデュース / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 25,969,738 shares |
| Treasury Shares at Period-End | — shares |
| Factors Behind Changes in Business Performance | The license agreement with an overseas pharmaceutical company, milestone revenue related to TLG-001, and the consolidation of メディプロデュース contributed to net sales. However, the Company recorded an operating loss due to research and development expenses, promotional expenses for the healthcare consumer products business, and operating and business expansion expenses for メディプロデュース, among other factors. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.On 1 July 2026, the Company acquired all shares of 株式会社メディプロデュース and consolidated its results. Net sales benefited from a license agreement with an overseas pharmaceutical company and milestone revenue related to TLG-001, while research and development expenses, promotional expenses for the healthcare consumer business, and operating and business expansion expenses for メディプロデュース resulted in an operating loss.